THYMOSIN ALPHA-1 10 mg

(1 customer review)
$35.00

    Purity > 99% – View Lab Test

  • PeptideThymosin Alpha-1 (TA1)
  • Amount10 mg per vial
  • FormLyophilized powder
  • Purity≥99% (HPLC COA available)
  • ManufactureGMP-certified facility
  • Storage (dry)Cool, dry place
  • After reconstitution2–8 °C (short-term); ?20 °C for long-term

Description

Thymosin Alpha-1 (TA1) 10 mg — Immune-Modulating Peptide for Host-Defense Research

Thymosin Alpha-1 (TA1) is a 28–amino-acid peptide originally isolated from
thymic extracts and later produced synthetically as a defined research molecule. In preclinical
and clinical research, TA1 has been investigated for its effects on T-cell function,
innate immunity, and host-defense pathways
in a variety of infectious, oncologic,
and immunologic models.

What It Is

  • Class: Thymic-derived immunomodulatory peptide analog
  • Length: 28 amino acids
  • Research focus: T-lymphocyte maturation/activation, innate immune signals,
    and host-response modulation under infectious or stress conditions.

Proposed Mechanisms (Preclinical)

T-Cell & Adaptive Immunity

  • Explored for enhancement of T-cell differentiation and activation,
    including CD4+ and CD8+ subsets.
  • Investigated for effects on Th1/Th2 balance and cytokine profiles
    in immune-challenge models.
  • Model-dependent modulation of regulatory T-cell and effector
    populations.

Innate Immunity & Host Defense

  • Studied for upregulation of innate immune receptors and
    pathogen-recognition pathways in preclinical systems.
  • Evaluated for changes in NK-cell activity, dendritic-cell function,
    and phagocytic responses
    .
  • Interest in synergy with vaccination or antimicrobial strategies
    in selected models.

Selected Research Highlights

  • Infectious Disease Models: TA1 has been studied as an immunomodulatory
    adjunct in viral and other infectious settings, focusing on host-response markers,
    viral-load dynamics, and clinical endpoints in select trials.
  • Oncology & Immunotherapy: Experimental and early clinical work has
    examined TA1 combined with chemotherapy, immunotherapy, or vaccination strategies for
    potential effects on immune parameters and outcomes.
  • Immune Dysregulation: Research includes evaluation in states of
    immune suppression or dysregulation, tracking changes in lymphocyte
    subsets, cytokines, and global immune competence markers.

Chemical & Handling Information

  • Type: Synthetic thymic peptide analog
  • Peptide length: 28 amino acids
  • Appearance: White to off-white lyophilized powder

Specifications

  • Peptide: Thymosin Alpha-1 (TA1)
  • Amount: 10 mg per vial
  • Form: Lyophilized powder
  • Purity: ?99% (HPLC); COA per lot available
  • Packaging: Sealed vials suitable for standard laboratory handling

Storage & Stability

  • Store lyophilized vials in a cool, dry place, protected from light.
  • Refrigeration or freezing of the lyophilized peptide is recommended for extended stability,
    according to laboratory SOPs.
  • After reconstitution, store at 2–8 °C for short-term use.
  • For long-term storage, aliquot and freeze at ?20 °C or below; avoid repeated freeze–thaw cycles.

1 review for THYMOSIN ALPHA-1 10 mg

  1. Scott Steele's avatar

    Scott Steele

    As described, couldn’t be any happier. Great overall 10/10

Add a review

Your email address will not be published. Required fields are marked *